918 terminated. 918 Phase 3, 117 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 918 | Terminated 918 |
| Phase 2 | 117 | Terminated 117 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma Best Supportive Care, Balstilimab, Botensilimab - Colorectal Cancer | Phase 3 | Terminated | Canadian Cancer Trials Group | 21 | 2026-03-31 | 2026-07-16 |
| Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma | Phase 2 / Phase 3 | Terminated | Children's Oncology Group | 2 | 2025-11-10 | 2026-10-05 |
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy - Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | Phase 3 | Terminated | PDS Biotechnology Corp. | 12 | 2025-05-30 | 2026-09-02 |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL Hypericin, Placebo - CTCL/ Mycosis Fungoides, CTCL | Phase 3 | Terminated | Soligenix | 70 | 2025-01-07 | 2026-07-13 |
| Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy® JPB898 (Induction and Maintenance), Opdivo-EU (Induction), Opdivo-US (Induction) - Melanoma | Phase 3 | Terminated | Sandoz | 52 | 2024-12-19 | 2026-02-24 |
| Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) FYB206, Keytruda - Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Terminated | Formycon AG | 25 | 2024-10-03 | 2025-06-26 |
| A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC BAT3306, EU-Keytruda®, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Bio-Thera Solutions | 162 | 2024-07-19 | 2025-12-02 |
| [68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose - Marginal Zone Lymphoma | Phase 3 | Terminated | Pentixapharm AG | 8 | 2024-05-20 | 2026-04-28 |
| A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) Pembrolizumab, Intismeran autogene, Surgery - Carcinoma, Squamous Cell, Skin Neoplasms | Phase 2 / Phase 3 | Terminated | Merck Sharp & Dohme LLC | 46 | 2024-04-18 | 2026-05-08 |
| BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer carboplatin, Paclitaxel, Recombinant humanized anti-PD-1 monoclonal antibody injection - Endometrial Cancer | Phase 2 / Phase 3 | Terminated | Bio-Thera Solutions | 5 | 2024-04-09 | 2025-08-14 |
| A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy Atezolizumab, Tiragolumab, Placebo - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Terminated | Hoffmann-La Roche | 56 | 2024-03-21 | 2026-06-10 |
| Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer Xevinapant, Placebo, cetuximab - Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Terminated | Groupe Oncologie Radiotherapie Tete et Cou | 19 | 2023-12-12 | 2025-05-09 |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) ADI PEG20, Placebo - Soft Tissue Sarcoma | Phase 3 | Terminated | Polaris Group | 218 | 2023-11-29 | 2026-06-25 |
| ATG Plus Low-dose PT-Cy for GVHD Prevention Cyclophosphamid, ATG - Hematologic Malignancy | Phase 3 | Terminated | Peking University People's Hospital | 66 | 2023-11-01 | 2025-06-03 |
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7 Regorafenib in combination with pembrolizumab, Loco-regional therapy - Carcinoma, Hepatocellular | Phase 3 | Terminated | Translational Research in Oncology | 45 | 2023-10-11 | 2026-03-09 |
| The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only 177Lu-DOTA-rosopatamb, Standard of Care - Metastatic Prostate Cancer | Phase 3 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 16 | 2023-08-29 | 2026-02-20 |
| REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 Luveltamab tazevibulin, Pegfilgrastim, Gemcitabine - Ovarian Cancer, Epithelial Ovarian Cancer | Phase 2 / Phase 3 | Terminated | Sutro Biopharma, Inc. | 600 | 2023-07-12 | 2025-09-23 |
| Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy eftilagimod alpha, Paclitaxel, placebo - Breast Carcinoma | Phase 2 / Phase 3 | Terminated | Immutep S.A.S. | 72 | 2023-05-22 | 2026-07-30 |
| Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy Oxycodone, Acetaminophen, Ketamine - Pain Management, Opioid Use | Phase 2 / Phase 3 | Terminated | Wake Forest University Health Sciences | 58 | 2023-04-18 | 2026-06-15 |
Showing 20 of 918. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (106) · Breast Neoplasms (105) · Prostatic Neoplasms (59) · Lung Neoplasms (55) · Neoplasm Metastasis (47) · Colorectal Neoplasms (43) · Leukemia, Myeloid, Acute (34) · Head and Neck Neoplasms (32) · Carcinoma, Hepatocellular (30) · Multiple Myeloma (28) · Pancreatic Neoplasms (27) · Colonic Neoplasms (26) · Melanoma (26) · Ovarian Neoplasms (26)
Neoplasms by Site (632) · Neoplasms by Histologic Type (394) · Hemic and Lymphatic Diseases (186) · Pathological Conditions, Signs and Symptoms (180) · Digestive System Diseases (176) · Digestive System Neoplasms (166) · Neoplasms, Glandular and Epithelial (165) · Urogenital Diseases (158) · Urogenital Neoplasms (146) · Skin and Connective Tissue Diseases (145) · Respiratory Tract Diseases (144) · Skin Diseases (143) · Lung Diseases (139) · Respiratory Tract Neoplasms (137)
Cisplatin (71) · Carboplatin (58) · Paclitaxel (56) · Radiotherapy (50) · Cyclophosphamide (44) · Gemcitabine (44) · Docetaxel (41) · Fluorouracil (35) · Capecitabine (34) · Rituximab (34) · Doxorubicin (30) · Dexamethasone (27) · pembrolizumab (27) · Etoposide (23) · Leucovorin (23)
Novartis Pharmaceuticals (31) · European Organisation for Research and Treatment of Cancer - EORTC (26) · Hoffmann-La Roche (23) · M.D. Anderson Cancer Center (18) · Merck Sharp & Dohme LLC (18) · Pfizer (16) · National Cancer Institute (NCI) (15) · Alliance for Clinical Trials in Oncology (13) · SWOG Cancer Research Network (12) · Sun Yat-sen University (11) · Amgen (10) · Gilead Sciences (10) · Spectrum Pharmaceuticals, Inc (10) · Bayer (9) · Assistance Publique - Hôpitaux de Paris (8)
United States (508) · France (248) · Germany (231) · Italy (222) · Canada (214) · Spain (211) · United Kingdom (203) · Belgium (169) · Poland (150) · South Korea (144) · Australia (138) · China (125) · Netherlands (120) · Hungary (112) · Russia (112)
PMID 37185961, PMID 37407274, PMID 38468440, PMID 41332393, PMID 26373676, PMID 29508247, PMID 30770362, PMID 33275766, PMID 34037241, PMID 34350976, PMID 34870327, PMID 36308441, PMID 37703506, PMID 38979716, PMID 39230120, PMID 42699559, PMID 10824073, PMID 11454999, PMID 14504060, PMID 14635083, PMID 14734470, PMID 14737100, PMID 14966097, PMID 15226337, PMID 15247354, PMID 15324695, PMID 15837996, PMID 15860850, PMID 16096437, PMID 16148022, PMID 16258090, PMID 16264158, PMID 16274985, PMID 16314401, PMID 16404430, PMID 16428482, PMID 16446331, PMID 16467544, PMID 16553139, PMID 16782926, PMID 16794899, PMID 16887481, PMID 17047401, PMID 17084621, PMID 17312332, PMID 17404368, PMID 17406356, PMID 17440164, PMID 17574960, PMID 17936405
2015 (14), 2016 (14), U10CA032102 (13), 2014 (12), 2023 (12), 2008 (10), 2017 (10), 2018 (10), 2019 (10), 2009 (9), 2005 (8), U10CA031946 (6), U10CA180868 (5), 2004 (4), U10CA021115 (4)